Azelastine/mometasone - Hanlim Pharmaceutical

Drug Profile

Azelastine/mometasone - Hanlim Pharmaceutical

Alternative Names: Mometasone/azelastine; Nasaflex Nasal Spray

Latest Information Update: 10 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanlim Pharmaceutical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Phthalazines; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Perennial allergic rhinitis

Most Recent Events

  • 10 Oct 2013 Registered and launched (prior to 10 October 2013) for Perennial allergic rhinitis in South Korea (Intranasal)
  • 01 Nov 2012 Hanlim Pharmaceutical completes its phase III trial in Perennial allergic rhinitis in South Korea (NCT01470053)
  • 01 Mar 2011 Phase-III clinical trials in Perennial allergic rhinitis in South Korea (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top